Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors.
Year: 2025
Type: conference-abstract
Study design: Study Protocol
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, St John of God Subiaco Hospital, Antwerp University Hospital, Macquarie University, Boehringer Ingelheim (Germany), Boehringer Ingelheim (United Kingdom), Japanese Foundation For Cancer Research, The University of Texas MD Anderson Cancer Center, Asan Medical Center, University of Ulsan, Clinica Universidad de Navarra, Universidad de Navarra, Tongji University, Shanghai East Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410823220